New pill aims to slow Parkinson's progression in Early-Stage patients
Disease control
Not yet recruiting
This study tests an experimental oral drug, GT-02287, in 111 people with early Parkinson's disease. Participants will receive either a low dose, high dose, or placebo for 48 weeks. The goal is to see if the drug can improve daily function and movement symptoms, and to check its s…
Phase: PHASE2 • Sponsor: Gain Therapeutics, Inc. • Aim: Disease control
Last updated May 06, 2026 16:02 UTC